PDK1 inhibitors (Tolero Pharmaceuticals Inc/ Brigham Young/University of Utah)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NamePDK1 inhibitors (Tolero Pharmaceuticals Inc/ Brigham Young/University of Utah)
Drug Alias NameHCI-1708SGI-1708
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitors3-phosphoinositide-dependent protein kinase 1 inhibitors
Targets3-phosphoinositide-dependent protein kinase 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTolero Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBrigham Young UniversityTolero Pharmaceuticals IncThe University Of Utah
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A